Abstract
Abstract
Background
We aimed to describe the acceptance of COVID-19 vaccine booster doses and factors influencing this among Thai university students.
Methods
A cross-sectional survey was conducted between July and September 2022. All university students in Thailand were eligible to participate. We explored the acceptance rate of COVID-19 vaccine booster doses and regular vaccines (if available) among university students. Associations between factors influencing the acceptance of vaccination were analyzed by multiple logistic regression analysis.
Results
A total of 322 participants were surveyed (78.9% female, age 18 to 49 years (mean = 22.6, standard deviation = 5.47)). Most participants (85.7%) were undergraduate students (Bachelor level), and a proportion (84.8%) had a background in health sciences studies. The proportions who accepted booster doses and regular vaccines were 52.8% and 69.3%, respectively. Vaccine accessibility was found to be significantly associated with the acceptance of booster doses (adjusted odds ratio (AOR) = 2.77, 95% confidence interval (CI) = 1.10–6.97), while the availability of scientific evidence (AOR = 3.44, 95% CI = 1.21–9.77) was significantly associated with the acceptance of regular vaccines.
Conclusions
This study contributes to addressing the knowledge gap regarding acceptance of COVID-19 vaccine booster doses among university students in Thailand. Our findings revealed that vaccine accessibility and the availability of scientific evidence, as well as vaccination costs, influenced individuals’ decisions around accepting vaccine booster doses. Further research should focus on the dynamics of vaccine acceptance to facilitate the development of targeted strategies and support vaccination policymaking in Thailand.
Funder
Wellcome Trust
the Wellcome Trust, Mahidol-Oxford Translational Innovation Partnership
Mahidol University
Publisher
Springer Science and Business Media LLC
Reference45 articles.
1. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19). 2022. https://www.cdc.gov/coronavirus/2019-ncov/your-health/about-covid-19.html. Accessed 15 July 2023
2. World Health Organization (WHO). Coronavirus disease (COVID-19). 2022. https://www.who.int/health-topics/coronavirus#tab=tab_1. Accessed 15 Jul 2023
3. Adams K, Rhoads JP, Surie D, Gaglani M, Ginde AA, McNeal T, Talbot HK, Casey JD, Zepeski A, Shapiro NI, et al. Vaccine effectiveness of primary series and booster doses against covid-19 associated hospital admissions in the United States: living test negative design study. BMJ. 2022;379: e072065. https://doi.org/10.1136/bmj-2022-072065.
4. Centers for Disease Control and Prevention (CDC). Effectiveness of 2, 3, and 4 COVID-19 mRNA vaccine doses among immunocompetent adults during periods when SARS-CoV-2 Omicron BA.1 and BA.2/BA.2.12.1 sublineages predominated—VISION Network, 10 States, December 2021–June 2022. 2022. https://www.cdc.gov/mmwr/volumes/71/wr/mm7129e1.htm. Accessed 9 Mar 2024
5. Sharif N, Alzahrani KJ, Ahmed SN, Dey SK. Efficacy, immunogenicity and safety of COVID-19 vaccines: a systematic review and meta-analysis. Front Immunol. 2021;12: 714170. https://doi.org/10.3389/fimmu.2021.714170.